Loading people...
Annie Mitsak is a Partner at Omega Funds in Boston, Massachusetts, leveraging over ten years of experience in academic licensing and venture investing to focus on the life sciences sector. Specializing in oncology, gene therapy, and RNA therapeutics, she previously served as an Associate Licensing Officer at the MIT Technology Licensing Office and an independent management consultant with Nelsen Biomedical. Her impressive investment track record includes serving as a Board Director at Trevi Therapeutics and a Board Observer for Checkmate Pharmaceuticals, which was acquired by Regeneron. She holds a Ph.D. and Master of Science in biomedical engineering from the University of Michigan, alongside a Bachelor of Science from the University of Virginia. Beyond evaluating early-stage therapeutics companies, Mitsak is also a dedicated advocate for the increased representation of women and underrepresented minorities in venture capital.
Annie Mitsak is a distinguished Principal at Omega Funds, a globally recognized healthcare investment firm with a strong track record in backing groundbreaking life science companies. In her pivotal role, Annie is deeply involved in the entire investment lifecycle, from initial deal sourcing and comprehensive due diligence to portfolio company management and strategic support. Her contributions are vital to Omega Funds' success in identifying and nurturing the next generation of healthcare leaders.
Her investment focus at Omega Funds is exclusively within the dynamic healthcare sector. Annie specializes in areas such as biotechnology, pharmaceuticals, and medical devices, with a keen interest in companies that are developing innovative therapies, disruptive technologies, and solutions addressing significant unmet medical needs. She actively seeks out opportunities in early-stage and growth-stage companies that possess strong scientific foundations, robust intellectual property, and experienced management teams capable of executing ambitious visions. Annie's analytical rigor and deep understanding of the life sciences landscape enable her to assess complex scientific data and market potential effectively.
Prior to her tenure at Omega Funds, Annie Mitsak built a solid foundation in both finance and the life sciences, equipping her with a unique perspective on healthcare investing. While specific details of her early career are not publicly detailed, professionals in her position typically bring backgrounds from top-tier investment banks, management consulting firms, or other venture capital/private equity roles, often complemented by advanced degrees in science, medicine, or business. This diverse experience provides her with the strategic insights necessary to navigate the intricate challenges and opportunities within the healthcare industry.
At Omega Funds, Annie plays a crucial role in identifying and evaluating promising companies that contribute to the firm's impressive portfolio of groundbreaking healthcare innovations. While individual investment specifics are often proprietary, her work directly supports Omega Funds' mission to invest in companies that are poised to make a significant impact on patient care and global health. Her dedication to fostering innovation and her strategic acumen make her a valuable asset to the Omega Funds team and the broader healthcare investment community.
Annie Mitsak is a Principal at Omega Funds, a leading healthcare investment firm. She is responsible for sourcing, evaluating, and managing investments in the life sciences sector.
Annie Mitsak primarily invests in the healthcare sector, focusing on biotechnology, pharmaceuticals, and medical devices. She seeks out innovative companies with strong scientific foundations.
Annie Mitsak works as a Principal at Omega Funds, a prominent investment firm specializing in the healthcare and life sciences industries.
